Wockhardt DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.89×	0.84×	3.56×	1.12×	1.00×
	0.85×	0.56×	−0.09×	2.28×	4.16×
	15.3%	12.6%	5.8%	−6.6%	−5.7%
	0.40×	0.40×	0.38×	0.36×	0.33×
	1.63×	1.63×	1.75×	2.09×	2.10×
	7.6%	3.8%	−1.3%	−12.7%	−16.2%
	4.6%	4.6%	−1.2%	−13.8%	−15.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

WOCKPHARMA₹1,922.90

Wockhardt Ltd.

· Pharma & Health

₹ CrorePeersBIOCON SYNGENE ASTERDM GLAND PPLPHARMA COHANCE LALPATHLAB NATCOPHARMMcap ₹31,151 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	1.00	1.12	3.56	0.84	0.89
Interest Burden (Pretax/EBIT) ×	4.16	2.28	-0.09	0.56	0.85
EBIT Margin %	-5.66	-6.58	5.84	12.60	15.32
Asset Turnover ×	0.33	0.36	0.38	0.40	0.40
Financial Leverage (Assets/Equity) ×	2.10	2.09	1.75	1.63	1.63
ROE (5-step product, year-end total equity) %	-16.22	-12.68	-1.26	3.85	7.58
ROE (owners' profit / average owners' equity) %	-15.52	-13.79	-1.22	4.58	4.58

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.